The relationship between XXXX levels and saphenous vein graft patency.

@entity1 @entity6 @entity453 @entity65 @entity560 @entity1851
OBJECTIVE: A growing body of evidence supports an association between @entity560 and @entity65 . Coronary artery bypass grafting surgery is a treatment modality for suitable @entity1 with @entity453 ; however, patency rates of saphenous vein grafts (SVGs) are low. In this study we aimed to determine the association between @entity560 levels and the SVG disease. METHODS: The study population included 180 @entity1 who had undergone a primary coronary artery bypass grafting surgery with at least one SVG and later had a control angiography because of clinical indications. @entity1 were divided into two groups: 100 @entity1 with SVG disease and 80 of them with patent SVG. RESULTS: The mean age of 180 @entity1 was 57.4  8.8 years, and 64.4% of the study population were @entity1 . The total number of SVGs was 364, and the mean number of SVGs to each @entity1 was 2.02  0.61. @entity560 levels were higher in the patent SVG group than in the SVG disease group (36.2  10.7 and 21.1  10.4, respectively; P<0.001). @entity1851 levels were significantly higher in the SVG disease group (8.3 vs. 6.5   mg/dl, P=0.001). In a multivariate regression analysis, current smoking, @entity6 , target artery diameter less than 1.5   mm, bypass time duration, and @entity560 levels remained as independent factors associated with SVG disease. CONCLUSION: Lower @entity560 levels are associated with occlusion of SVGs in @entity1 with @entity453 .
